These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 34089308)

  • 1. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
    Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
    ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.
    Siddiqi OK; Ruberg FL
    Trends Cardiovasc Med; 2018 Jan; 28(1):10-21. PubMed ID: 28739313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid cardiomyopathy.
    Kristen AV
    Herz; 2020 May; 45(3):267-271. PubMed ID: 32107564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
    Ruberg FL; Maurer MS
    JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
    Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G
    Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
    Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
    Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ten questions about transthyretin amyloidosis].
    Giovannetti A; Accietto A; Massa P; Leone O; Guaraldi P; Saturi G; Caponetti AG; Sguazzotti M; Ponziani A; Gagliardi C; Galiè N; Cortelli P; Longhi S; Biagini E
    G Ital Cardiol (Rome); 2022 Sep; 23(9):676-685. PubMed ID: 36039718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology, diagnosis, and management of cardiac amyloidosis.
    Bashir Z; Younus A; Dhillon S; Kasi A; Bukhari S
    J Investig Med; 2024 Oct; 72(7):620-632. PubMed ID: 38869161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy.
    Teng C; Li P; Bae JY; Pan S; Dixon RAF; Liu Q
    Clin Cardiol; 2020 Nov; 43(11):1223-1231. PubMed ID: 32725834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
    Brito D; Albrecht FC; de Arenaza DP; Bart N; Better N; Carvajal-Juarez I; Conceição I; Damy T; Dorbala S; Fidalgo JC; Garcia-Pavia P; Ge J; Gillmore JD; Grzybowski J; Obici L; Piñero D; Rapezzi C; Ueda M; Pinto FJ
    Glob Heart; 2023; 18(1):59. PubMed ID: 37901600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in pharmacotherapy for cardiac amyloidosis.
    Spoladore R; Falasconi G; Marcatti M; Di Maio S; Fiore G; Slavich M; Margonato A; Turco A; Fragasso G
    Expert Opin Pharmacother; 2021 Mar; 22(4):469-481. PubMed ID: 33043721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
    Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
    Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the Treatment of Cardiac Amyloidosis.
    Macedo AVS; Schwartzmann PV; de Gusmão BM; Melo MDT; Coelho-Filho OR
    Curr Treat Options Oncol; 2020 Apr; 21(5):36. PubMed ID: 32328845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
    Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
    Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transthyretin amyloid cardiomyopathy.
    Garcia-Pavia P; Domínguez F; Gonzalez-Lopez E
    Med Clin (Barc); 2021 Feb; 156(3):126-134. PubMed ID: 33138983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.